Humana Inc. (NYSE:HUM) Expected to Post Quarterly Sales of $21.17 Billion

Wall Street brokerages expect Humana Inc. (NYSE:HUM) to report $21.17 billion in sales for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Humana’s earnings. The lowest sales estimate is $20.68 billion and the highest is $21.75 billion. Humana reported sales of $19.06 billion in the same quarter last year, which would suggest a positive year over year growth rate of 11.1%. The business is scheduled to report its next earnings results on Wednesday, February 2nd.

According to Zacks, analysts expect that Humana will report full-year sales of $83.29 billion for the current year, with estimates ranging from $82.69 billion to $83.76 billion. For the next year, analysts forecast that the firm will post sales of $92.39 billion, with estimates ranging from $89.90 billion to $96.15 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Humana.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 3rd. The insurance provider reported $4.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.61 by $0.22. Humana had a return on equity of 14.95% and a net margin of 3.30%. The firm had revenue of $20.70 billion during the quarter, compared to analysts’ expectations of $20.91 billion. During the same period in the previous year, the business earned $3.08 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis.

Several brokerages have issued reports on HUM. Citigroup upped their target price on Humana from $510.00 to $528.00 and gave the company a “buy” rating in a report on Tuesday, November 9th. Credit Suisse Group upped their target price on Humana from $500.00 to $513.00 and gave the company an “outperform” rating in a report on Thursday, November 4th. Cowen began coverage on Humana in a report on Thursday, September 9th. They issued an “outperform” rating and a $479.00 target price for the company. Mizuho upped their target price on Humana from $480.00 to $500.00 and gave the company a “buy” rating in a report on Wednesday, November 10th. Finally, Royal Bank of Canada increased their price target on Humana from $479.00 to $525.00 and gave the stock an “outperform” rating in a report on Thursday, November 4th. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Humana presently has an average rating of “Buy” and an average target price of $503.51.

In other news, Director David A. Jr/Ky Jones sold 4,800 shares of the stock in a transaction dated Thursday, September 16th. The stock was sold at an average price of $401.00, for a total value of $1,924,800.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Bruce D. Broussard sold 50,006 shares of the stock in a transaction dated Friday, November 5th. The shares were sold at an average price of $454.70, for a total value of $22,737,728.20. The disclosure for this sale can be found here. 0.40% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its stake in Humana by 18.7% during the 2nd quarter. FMR LLC now owns 10,241,494 shares of the insurance provider’s stock worth $4,534,114,000 after buying an additional 1,612,251 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Humana by 0.4% in the 2nd quarter. Vanguard Group Inc. now owns 10,047,296 shares of the insurance provider’s stock valued at $4,448,139,000 after purchasing an additional 38,633 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Humana by 10.7% in the 3rd quarter. Wellington Management Group LLP now owns 6,465,032 shares of the insurance provider’s stock valued at $2,515,867,000 after purchasing an additional 626,652 shares during the last quarter. State Street Corp grew its stake in shares of Humana by 2.9% in the 2nd quarter. State Street Corp now owns 5,624,088 shares of the insurance provider’s stock valued at $2,493,769,000 after purchasing an additional 156,025 shares during the last quarter. Finally, Capital International Investors grew its stake in shares of Humana by 3.9% in the 2nd quarter. Capital International Investors now owns 4,025,016 shares of the insurance provider’s stock valued at $1,781,940,000 after purchasing an additional 151,466 shares during the last quarter. Institutional investors and hedge funds own 91.75% of the company’s stock.

NYSE:HUM traded down $1.04 during trading hours on Friday, hitting $436.19. The company had a trading volume of 476,551 shares, compared to its average volume of 879,925. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 0.70. The company has a 50-day moving average of $430.24 and a 200 day moving average of $431.95. The company has a market cap of $56.07 billion, a P/E ratio of 21.06, a P/E/G ratio of 1.58 and a beta of 0.94. Humana has a 1 year low of $370.22 and a 1 year high of $475.44.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 28th. Investors of record on Friday, December 31st will be paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Thursday, December 30th. Humana’s payout ratio is 13.52%.

About Humana

Humana Inc engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts.

Featured Story: Net Margin – Understanding the Different Kinds of Profit

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.